Drug intelligence / Profile preview

cyclophosphamide + novobiocin + thiotepa

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), novobiocin (a coumeromycin antibiotic), and thiotepa (an alkylating agent). The combination was studied primarily for treatment of advanced breast cancer. Novobiocin was included in this regimen based on its ability to potentially reverse alkylator drug resistance by inhibiting DNA repair, thus improving the efficacy of high-dose chemotherapy. The regimen is typically administered with autologous marrow support.

Targets

DNA

Beyond the preview

Go deeper on cyclophosphamide + novobiocin + thiotepa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + novobiocin + thiotepa.

Explore the full profile